DELNOVA was selected to present at IMCAS, the premier global congress in aesthetic medicine for the final stage of the Innovation Tank Competition Friday January 31st, 2025 at the Palais des Congrès in Paris, France.
DelNova will showcase groundbreaking progress towards its first-in-class drug candidate, ReViVox®; a locally administered reversal/rescue drug product to address botulinum neurotoxin (BoNT) side effects, while underscoring best patient outcomes. BoNTs include US brands such as BOTOX®, DYSPORT®, XEOMIN® AND JEUVEAU®.
DelNova’s vision is overwhelmingly supported by medical aesthetic practitioners worldwide. Our product vision is to optimize outcomes from neuromodulator procedures in facial rejuvenation and will be stocked everywhere patients are treated with aesthetic injectables. Despite widespread use of neuromodulators, it is known that inadvertent spread or overuse of toxin, may result in undesirable conditions of muscle paralysis or weakness, manifested as eyelid or brow ptosis, unnatural facial expression, and facial-feature misalignment. The introduction of ReViVox® as an effective eraser, will boost confidence for both patients and physicians.
About IMCAS World Congress
IMCAS World Congress is a medical aesthetics-dedicated event that gathers over 18,700 healthcare and industry professionals to provide a global overview of the latest breakthroughs and innovations in the dermatology, plastic surgery, and aging science community. For more information, please visit: https://www.imcas.com/en/attend/imcas-world-congress-2025
ABOUT DELNOVA, Inc. (www.delnova.net)
DelNova, Inc. is a privately held early-stage biopharmaceutical company developing innovative therapeutics using clinically validated molecules linked to advances in drug delivery to solve unmet medical needs. The company’s lead clinical candidate, ReViVox®, is designed for the rescue of complications caused by off-target muscle paralysis following aesthetic and medical neurotoxin procedures.
About DelNova, Inc.
Solving Botulinum Treatment Complications
